News and Events

To sign up to our mailing list and receive updates and stories from the programme, please click the link below and fill out the form.

142 results

To mark this year’s World Antimicrobial Awareness Week (WAAW) theme, we ask some of our partners what the Fleming Fund has meant to them.

The Fleming Fund was created in 2015-16 to strengthen national AMR surveillance systems in low- and middle-income countries (LMICs) and supported 23 countries during its first phase of implementation from 2018 to 2022.

At the end of October, the Fleming Fund hosted a virtual Global Learning Summit to celebrate its achievements, share learning and highlight the legacy of the programme.

The World Health Organization (WHO) has released its Global Antibiotic Resistance Surveillance Report 2025, revealing that one in six bacterial infections worldwide in 2023 were resistant to antibiotics.

The largest retrospective study on antibiotic resistance (AMR) in Africa highlights the need for major investments to enhance laboratory capabilities and healthcare access.

The threat of mortality, morbidity, and economic loss associated with antimicrobial resistance (AMR) poses a significant burden on countries in the South East Asia region.

Two landmark projects aimed at strengthening the Caribbean’s capacity to fight antimicrobial resistance (AMR) were launched on 5 May, at an event in Barbados with regional and international health leaders in attendance.

A free online programme developed by the Fleming Fund and The Open University to strengthen the global response to antimicrobial resistance (AMR) has been relaunched with updated content across all 25 courses.

At the recent Regional World Health Summit in New Delhi on Emerging Infectious Diseases (EID) preparedness in South East Asia, hosted by Jhpiego, the Fleming Fund led a critical panel session: ‘AMR – The Unseen Threat in EID Preparedness’.

A major driver of AMR is the inappropriate use of antimicrobials. This is a common issue in many resource-limited countries with poor access to the correct medicines and treatment.